Trials / Completed
CompletedNCT05553808
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Docetaxel was administered as IV infusion. |
| DRUG | Feladilimab | Feladilimab was administered as IV infusion. |
Timeline
- Start date
- 2019-01-24
- Primary completion
- 2021-09-23
- Completion
- 2021-09-23
- First posted
- 2022-09-23
- Last updated
- 2023-01-19
- Results posted
- 2023-01-19
Locations
43 sites across 12 countries: United States, Canada, France, Germany, Italy, Netherlands, Poland, Romania, Russia, South Korea, Spain, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05553808. Inclusion in this directory is not an endorsement.